Collaborative research team solves cancer cell mutation mystery

Susan McKenna, Alex Kreig, and Siv Schwink
5/18/2015

Research breakthrough has implications for better targeted cancer treatment protocols

 

Professor of Physics and of Bioengineering Jun Song
Professor of Physics and of Bioengineering Jun Song
More than 500,000 people in the United States die each year of cancer-related causes. Now, emerging research has identified the mechanism behind one of the most common mutations that helps cancer cells to replicate limitlessly.

Approximately 85 percent of cancer cells obtain their limitless replicative potential through the reactivation of a specific protein called telomerase (TERT). Recent cancer research has shown that highly recurrent mutations in the promoter of the TERT gene are the most common genetic mutations in many cancers, including adult glioblastoma and hepatocellular carcinoma.

TERT stabilizes chromosomes by elongating the protective element at the end of each chromosome in a cell. Scientists have discovered that cells harboring these mutations aberrantly increase TERT expression, effectively making them immortal.

Now, a collaborative team of researchers at the University of Illinois at Urbana-Champaign and at the University of California, San Francisco, has uncovered the mechanisms by which mutations result in elevated TERT expression. The team’s findings, published in the May 14 issue of Science, have exciting implications for new, more precise and personalized cancer treatments with fewer side effects compared with current treatments.

Physics Illinois postdoctoral researcher Hans Tomas Rube played a key role in the discovery
Physics Illinois postdoctoral researcher Hans Tomas Rube played a key role in the discovery
By integrating computational and experimental analyses, the researchers, led by Illinois biological physicist Jun S. Song and UCSF cancer biologist Joseph Costello, identified that the mechanism of increased TERT expression in tumor tissue relies on a specific transcription factor that selectively binds the mutated sequences. A transcription factor is a protein that binds specific DNA sequences and regulates how its target genes are expressed (in this case the gene that expresses TERT). Thus, the TERT mutations act as a new binding site for the transcription factor that controls TERT expression. The newly identified transcription factor does not recognize the normal TERT promoter sequence, and thus, does not regulate TERT in healthy tissue.

The team’s work further showed that the same transcription factor recognizes and binds the mutant TERT promoter in tumor cells from four different cancer types, underscoring that this is a common mechanism of TERT reactivation.

The identified transcription factor and its regulators have great potential for the development of new precision therapeutic interventions in cancers that harbor the TERT mutations. A treatment that would inhibit TERT in a targeted cancer-cell-specific manner would bypass the toxicities associated with current treatments that inadvertently also target TERT in normal healthy cells.

Based on these new findings, the team is now conducting a variety of experiments designed to test whether inhibiting the transcription factor activity would not only turn down TERT expression, but might also result in selective cancer cell death.

This project was enhanced by the complementary analysis conducted by three research groups located across the country. Joseph F. Costello’s laboratory at UCSF is linked to the UCSF Medical Center and the Helen Diller Family Comprehensive Cancer Center, which allowed for access to human tumor samples that generated the cell cultures and produced relevant models. Jun Song's group at Illinois provided advanced computational analysis of the genomic data and predictions that narrowed in on possible mechanisms behind the previously identified mutation. Finally, through single-molecule analysis, Su-A Myong’s lab at Illinois provided verification that the proposed mechanism operated in the suggested matter.

The researchers at Illinois include H. Tomas Rube, Alex Kreig, Sua Myong, and Song; the UCSF collaborators include Robert J. A. Bell, Andrew Mancini, Shaun F. Fouse, Raman P. Nagarajan, Serah Choi, Chibo Hong, Daniel He, Melike Pekmezci, John K. Wiencke, Margaret R. Wrensch, Susan M. Chang, Kyle M. Walsh, and Joseph F. Costello.

This research was funded by by NCI R01CA163336 (J.S.S.), the Sontag Foundation Distinguished Scientist Award (J.S.S.), NCI P50CA097257 and P01CA118816-06 (M.S.B., S.M.C., J.F.C.); NCI R01CA169316-01 (J.F.C.), the Grove Foundation, the Karen Osney Brownstein Endowed Chair (J.F.C.), the Anne and Jason Farber Foundation, and a gift from the Dabbiere family. Additional support was provided by NCI R25CA112355 (K.M.W.), R01CA52689 (K.M.W., J.K.W., M.R.W.), P50CA097257 (K.M.W., M.R.W.), the Stanley D. Lewis and Virginia S. Lewis Endowed Chair in Brain Tumor Research, the Robert Magnin Newman Endowed Chair in Neuro-oncology, the Founder Professorship from the Grainger Engineering Breakthroughs Initiative (J.S.S.), and donations from families and friends of John Berardi, Helen Glaser, Elvera Olsen, Raymond E. Cooper, and William Martinusen. Provisional patent application (application number: 62/145,579) has been filed by the University of California, San Francisco, and University of Illinois. All transcriptome sequencing data have been deposited in the European Genome-phenome Archive under accession number EGAS00001001242.

Recent News

  • Accolades
  • Atomic, Molecular, and Optical Physics

Assistant Professor Bryce Gadway of the Department of Physics at the University of Illinois Urbana-Champaign has been selected for the 2017 U.S. Air Force Young Investigator Research Program. Gadway is among 43 early-career scientists and engineers nationwide to receive this three-year award of $450,000. U.S. Air Force Young Investigators are selected based on demonstrated exceptional ability and promise for conducting basic research in scientific and engineering areas identified as strategic to the US Air Force mission.

  • In the Media

A company founded by a University of Illinois physics professor has raised more than $1.5 million in venture funding this year, graduated from the UI Research Park's EnterpriseWorks incubator and this week announced it was selected for a project by NASA.

At its new 12,000-square-foot facility on Kenyon Road near Interstate 74 in Champaign, Inprentus manufactures diffraction gratings, an advanced prism of sorts used in laboratories around the world.

The company was founded by Peter Abbamonte in 2012.

  • Outreach

Because physics has its dark mysteries too, we have appropriated Halloween! Watch our Dark Matter Day video on our YouTube channel!

Watch the short video Dark Matter and hear leading-edge scientists explain what we know about one of the greatest mysteries of our time. What could it be? How do we know it’s there? And what ingenious methods are scientists, working in different subdisciplines of physics and astronomy around the globe, using to detect dark matter?

Astrophysicist Jeff Filippini, astronomer Felipe Menanteau, experimental nuclear physicist Liang Yang, theoretical particle physicist Jessie Shelton, and experimental particle physicist Ben Hooberman provide an accessible overview of some of the most exciting scientific research that is ongoing today.

This educational outreach video was produced by the Department of Physics at the University of Illinois at Urbana Champaign, under the direction of U of I Public Affairs Video Services.